A new mini-review was published in Oncotarget’s Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumours.”
As highlighted in the abstract of this paper, malignant peripheral nerve sheath tumours (MPNSTs) are aggressive, Ras-driven sarcomas characterised by the loss of the NF1 tumour suppressor gene and the hyperactivation of MEK and CDK4/6 kinases.
Currently, MPNSTs lack effective therapies.
Recently, the authors demonstrated the remarkable efficacy of dual CDK4/6-MEK inhibition in mice with de novo MPNSTs, which was further enhanced by targeting the immune checkpoint protein PD-L1.
This triple combination therapy, targeting CDK4/6, MEK, and PD-L1, resulted in prolonged MPNST regression and improved survival, although most tumours eventually developed drug resistance.
LISTEN TO THE LATEST UPDATE ON HRD TESTING IN AUSTRALIA | WITH ANDREW FELLOWES AND JEFF GOH | ONCOLOGY NETWORK EXCLUSIVE
In their latest mini review, researchers Joshua J.Lingo, Ellen Voigt, and Dawn E. Quelle from the University of Iowa’s Cancer Biology Graduate Programme, Holden Comprehensive Cancer Centre, Medical Scientist Training Programme, Department of Neuroscience and Pharmacology, and Department of Pathology, explore the immune activation phenotype caused by CDK4/6-MEK inhibition in MPNSTs, emphasising the unique involvement of intratumoral plasma cell accumulation. They also discuss how PD-L1 and FOXM1, a tumour-promoting transcription factor, are functionally linked and may serve as key mediators of resistance to CDK4/6-MEK targeted therapies.
Source: Impact Journals LLC
